Schwartz P E, Cracchiolo B M, Cole L A
Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Anticancer Res. 1996 Jul-Aug;16(4B):2135-9.
The past seven years has witnessed the development of research assays and now commercial assays for the measurement of a fragment of the beta subunit of human chorionic gonadotropin (beta-hCG). This fragment has been called the beta core fragment (beta-core), urinary gonadotropin fragment (UGF) and most recently urinary gonadotropin peptide (UGP). Clinical applications of UGP have been pursued most often but not exclusively in gynecologic oncology. This review presents evidence for a role for UGP in (1) the screening of women at high risk for ovarian cancer by virtue of their family history, (2) the differentiation of benign pelvic masses from malignant ones, particularly in premenopausal women and (3) monitoring women known to have previously been diagnosed with ovarian cancer and possibly cervical and advanced uterine cancer to determine efficacy of therapy.
在过去七年中，用于测量人绒毛膜促性腺激素β亚基片段（β-hCG）的研究检测方法以及现在的商业检测方法得到了发展。这个片段被称为β核心片段（β-core）、尿促性腺激素片段（UGF），最近又被称为尿促性腺激素肽（UGP）。UGP的临床应用最常被探索，不过并非仅仅局限于妇科肿瘤学领域。本综述提供了证据，证明UGP在以下方面发挥作用：（1）凭借家族病史对卵巢癌高危女性进行筛查；（2）区分良性盆腔肿块与恶性肿块，尤其是在绝经前女性中；（3）监测已知先前被诊断患有卵巢癌以及可能患有宫颈癌和晚期子宫癌的女性，以确定治疗效果。
